Harbeck, N; Wrobel, D; Zaiss, M; Guth, D; Distelrath, A; Terhaag, J; Lorenz, A; Bartsch, R; Breitenstein, U; Schwitter, M; Balic, M; Jackisch, C; Muller, V; Rinnerthaler, G; Schmidt, M; Zaman, K; Schinkothe, T; Luftner, D.
Interim analysis (n=150) of the multi-national, prospective, non-interventional ELEANOR study observing real-life extended adjuvant treatment with neratinib in patients with HER2+/ HR+ early breast cancer (eBC)
ANN ONCOL. 2022; 33: S157-S157.
Doi: 10.1016/j.annonc.2022.03.091
[Poster]
Web of Science
FullText
FullText_MUG